Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Melody A. Cobleigh"'
Autor:
Virginia Paton, Gracie Lieberman, Melody A. Cobleigh, Debasish Tripathy, Nicholas J. Robert, Charles L. Vogel, Louis Fehrenbacher, Janet M. Wolter, Steven Shak, Susy Scholl, Dennis J. Slamon
Publikováno v:
Journal of Clinical Oncology. 41:1501-1510
PURPOSE Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody as a single agent was evalu
Autor:
Vincent Antao, Mohammad Jahanzeb, Denise A. Yardley, Joyce O'Shaughnessy, Peter A. Kaufman, Ginny Mason, Adam Brufsky, Sara A. Hurvitz, Laura Chu, Melody A. Cobleigh, Hope S. Rugo, Sandra M. Swain, Debu Tripathy, Haocheng Li
Publikováno v:
Clinical Cancer Research. 26:1105-1113
Purpose: We report treatments and outcomes in a contemporary patient population with HER2-positive metastatic breast cancer (MBC) by hormone receptor (HR) status from the Systemic Therapies for HER2-positive Metastatic Breast Cancer Study (SystHERs).
Autor:
Melody A. Cobleigh, Stewart J. Anderson, Norman Wolmark, Douglas W. Arthur, Allison Zibelli, J. Lyons, Marianne K. Melnik, Melissa S. Dillmon, Matthew L. Hill, David S. Parda, Eleftherios P. Mamounas, Thomas B. Julian, Samantha A. Seaward, Dennis L. Carter, V.S. Kavadi, Lavanya Tiriveedhi, Gustav Magrinat, Sushil Beriwal, Rachel Rabinovitch, Kalliopi P. Siziopikou
Publikováno v:
J Clin Oncol
PURPOSE Preclinical studies report that trastuzumab (T) can boost radiotherapy (RT) effectiveness. The primary aim of the B-43 trial was to assess the efficacy of RT alone vs concurrent RT plus T in preventing recurrence of ipsilateral breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff244299bf20a477f0d82018364ef159
https://europepmc.org/articles/PMC8462554/
https://europepmc.org/articles/PMC8462554/
Autor:
Sandra M. Swain, Vincent Antao, Haocheng Li, Debu Tripathy, Joyce O'Shaughnessy, Laura Chu, Ginny Mason, Peter A. Kaufman, Denise A. Yardley, Sara A. Hurvitz, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Melody A. Cobleigh
Publikováno v:
The oncologist, vol 25, iss 2
The Oncologist
The Oncologist
Background Limited data exist describing real‐world treatment of de novo and recurrent HER2‐positive metastatic breast cancer (MBC). Materials and Methods The Systemic Therapies for HER2‐Positive Metastatic Breast Cancer Study (SystHERs) was a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f85b6f5b4b0427599690acf0ecde9c9
https://escholarship.org/uc/item/3141135z
https://escholarship.org/uc/item/3141135z
Autor:
Timothy Yung, Melody A. Cobleigh, Abde M. Abukhdeir, Deri Morgan, Molly DiScala, Matthew S. Najor
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 6, p e0234146 (2020)
PLoS ONE, Vol 15, Iss 6, p e0234146 (2020)
Approximately 20% of breast cancers are HER2-positive. Trastuzumab has improved patient outcomes significantly for these cancers. However, acquired resistance remains a major hurdle in the clinical management of these patients. Therefore, identifying
Autor:
Haocheng Li, Ginny Mason, Denise A. Yardley, Sara A. Hurvitz, Melody A. Cobleigh, Sandra M. Swain, Adam Brufsky, Hope S. Rugo, Mohammad Jahanzeb, Peter A. Kaufman, Debu Tripathy, Vincent Antao, Laura Chu, Joyce O'Shaughnessy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(8)
Purpose:Patients with HER2-positive metastatic breast cancer (MBC) with central nervous system (CNS) metastasis have a poor prognosis. We report treatments and outcomes in patients with HER2-positive MBC and CNS metastasis from the Systemic Therapies
Autor:
Meghna Samant, Dan Lu, Joo Hee Yi, Pierfranco Conte, Melody A. Cobleigh, Yuying Gao, Bei Wang, Ellie Guardino, Sandhya Girish, Mothaffar F. Rimawi, Jin Yan Jin
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising the humanized monoclonal antibody trastuzumab linked to DM1, a highly potent cytotoxic agent. A population pharmacokinetic (PK) analysis was performed to estimate typica
Autor:
Kathy D. Miller, George W. Sledge, Robert Gray, Edith A. Perez, Nancy E. Davidson, Kirsten Vang Nielsen, Maura N. Dickler, Bryan P. Schneider, Gail H. Vance, Ann D. Thor, Melody A. Cobleigh, Sven Müller, Julie Gralow, Sunil Badve, Tamara Shenkier, Joseph A. Sparano, Fei Shen, Lang Li, Guanglong Jiang, Milan Radovich
Publikováno v:
Clinical Cancer Research. 19:1281-1289
Purpose: Clinically validated biomarkers for anti-angiogenesis agents are not available. We have previously reported associations between candidate VEGFA single-nucleotide polymorphisms (SNP) and overall survival (OS) in E2100. The associations betwe
Autor:
D. Grun, Giampietro Gasparini, Sophie Marguet, Melody A. Cobleigh, Stefan Michiels, Shani Paluch-Shimon, DJ Slamon, G. von Minckwitz, Charles L. Vogel, S.R.D. Johnston, David Cameron, L. Pugliano, Valentina Nekljudova, Frédérique Penault-Llorca, Marc Buyse, Michel Marty, Jana Barinoff, Bella Kaufman, Martine Piccart, A. Di Leo
Publikováno v:
Michiels, S, Pugliano, L, Marguet, S, Grun, D, Barinoff, J, Cameron, D, Cobleigh, M, Di Leo, A, Johnston, S, Gasparini, G, Kaufman, B, Marty, M, Nekjudova, V, Paluch-Shimon, S, Penault-Llorca, F, Slamon, D, Vogel, C, Von Minckwitz, G, Buyse, M & Piccart, M 2016, ' Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer ', Annals of Oncology . https://doi.org/10.1093/annonc/mdw132
Background: The gold standard end point in randomized clinical trials in metastatic breast cancer (MBC) is overall survival (OS). Although therapeutics have been approved based on progression-free survival (PFS), its use as a primary end point is con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c12b631895c430156ceb45546691abf1
https://hdl.handle.net/20.500.11820/11af6e5a-7d2c-4265-9b78-93efb64402da
https://hdl.handle.net/20.500.11820/11af6e5a-7d2c-4265-9b78-93efb64402da
Autor:
David M. Loesch, Nicholas J. Robert, Robert N. Raju, Robert M. Sayre, Dennis J. Slamon, Kathy S. Albain, Elizabeth Valentine, Brian Leyland-Jones, Lea Fuchs, Cecelia McCullough, Lina Asmar, R. J. Belt, Melody A. Cobleigh, Des Ilegbodu
Publikováno v:
Journal of Clinical Oncology. 24:2786-2792
Purpose This randomized, multicenter, phase III trial evaluated the efficacy and safety of trastuzumab and paclitaxel with or without carboplatin as first-line therapy for women with HER-2–overexpressing metastatic breast cancer (MBC). Patients and